Findings from our FreeStyle Libre/GLP-1 Analysis

New data demonstrate that people are relying on both GLP-1s and continuous glucose monitoring to manage diabetes.

Strategy and Strength|Sep.28, 2023

Type 2 diabetes is growing rapidly and is one of the world’s most prevalent chronic conditions. Weight-loss drugs, such as GLP-1s, will not eliminate the need for other tools people use to manage diabetes, such as continuous glucose monitoring (CGM) systems.

Data from a September analysis of these weight-loss drugs and of continuous glucose monitoring (including our FreeStyle Libre CGM systems) show a growing number of people are using these tools together in their treatment of diabetes.

In our analysis, we also found that FreeStyle Libre sensor adherence — in other words, the number of days a sensor is worn — is higher for those who also use GLP-1 therapy.

Read the full analysis here.

Important safety information

FreeStyle Libre 14 day, FreeStyle Libre 2 and FreeStyle Libre 3 systems

Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or for safety info.


The product images are for illustrative purposes only.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.

No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.

This website and the information contained herein is intended for use by residents of the United States.